60 Degrees Pharmaceutical... (SXTP)
0.91
0.01 (1.00%)
At close: Jan 15, 2025, 12:12 PM
undefined% (undefined)
| Bid | 0.9 |
| Market Cap | 2.10M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -9.64 |
| PE Ratio (ttm) | -0.09 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.92 |
| Volume | 99,686 |
| Avg. Volume (20D) | 585,478 |
| Open | 0.89 |
| Previous Close | 0.90 |
| Day's Range | 0.88 - 0.93 |
| 52-Week Range | 0.70 - 11.88 |
| Beta | undefined |
About SXTP
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, cand...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 12, 2023
Employees 3
Stock Exchange NASDAQ
Ticker Symbol SXTP
Website https://60degreespharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for SXTP stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
Next Earnings Release
60 Degrees Pharmaceuticals Inc. is scheduled to release its earnings on Mar 31, 2025,
during market hours.
Analysts project revenue of $234.00K, reflecting a 86.19% YoY growth and earnings per share of -0.65, making a -87.69% decrease YoY.
Analysts project revenue of $234.00K, reflecting a 86.19% YoY growth and earnings per share of -0.65, making a -87.69% decrease YoY.
1 month ago ·
Source
+34.48%
60 Degrees Pharmaceuticals shares are trading high...
Unlock content with
Pro Subscription
5 months ago ·
Source
+24.06%
60 Degrees Pharmaceuticals shares are trading higher after the company reported a year-over-year increase in Q2 financial results.
